MAGENTIQ EYE (see Pulse 2.0 profile here), an innovator in AI-based gastroenterology decision-support software, has completed its Series A funding round. The round was led by aMoon, Israel’s largest HealthTech investment fund, with participation from Norgine Ventures BV (Netherlands), Nina Capital (EU & USA), Namarel Ventures SL (Spain), Nova Capital (Italy), and private investors Sake Bosch and Roon Doornink (USA).
In conjunction with the investment, aMoon partner Roy Wiesner will join MAGENTIQ EYE’s board of directors, bringing valuable insights and experience in health tech.
MAGENTIQ EYE’s FDA and CE-approved software, MAGENTIQ-COLO, enhances polyp detection during colonoscopies, improving adenoma detection rates. It also offers real-time insights and includes features such as polyp size categorization and AI-generated reports.
The company is conducting clinical trials for diagnostic tools targeting diseases of the lower and upper gastrointestinal tract and is developing automated quality indicators for GI procedures. Proceeds from this funding round will support further development and commercial growth in the USA, Europe, and globally through partnerships with industry leaders.
KEY QUOTES:
“This investment round marks a major milestone for MAGENTIQ EYE. We are thrilled to welcome aMoon and Roy Wiesner to our journey. With aMoon’s support, we will accelerate innovation and market access, meeting the growing demand reflected in our robust pipeline of trial and purchase requests across the U.S. and Europe, and bring our advanced diagnostic tools to more physicians and patients around the world.”
Dror Zur, Ph.D., founder and CEO of MAGENTIQ EYE
“We are proud to partner with MAGENTIQ EYE, a company leading the charge in AI-powered colonoscopy. MAGENTIQ’s solution stands out as the most accurate in the market, with the broadest set of features, cost-effective scalability, and platform flexibility across GI and laparoscopic applications. We’re also encouraged by the strong early commercial traction and the growing interest from major strategic players looking to collaborate. This investment reflects aMoon’s commitment to backing transformative health tech solutions that can dramatically improve patient outcomes worldwide.”
Roy Wiesner
